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Abstract
Background:  The true relationship between methylenetetrahydrofolate reductase C677T
homozygosity and risk of recurrent spontaneous abortion is unknown, and it is unclear if women
with these mutations should be anticoagulated during pregnancy.
Objectives: We report a series of 8 patients with this issue and review the current literature.
Methods:  8 patients (3 of whom were actively pregnant) were referred with histories of
spontaneous fetal loss; hypercoaguability work-ups revealed each were homozygous for the
MTHFR C677T mutation without other thrombophilias.
Results: In the 3 women who have conceived, treatment with LMW heparin during pregnancy led
to two full-term births and one additional pregnancy without complication. For the 5 who have not,
we recommended treatment with LMW heparin upon conception.
Conclusion: We provide evidence to support the relationship between MTHFR C677T mutations
and recurrent fetal loss, and to suggest that anticoagulation of these patients during pregnancy can
lead to a successful pregnancy outcome.
Background
There is growing evidence that thrombophilia defects can
impact pregnancy outcomes. It is already well-known that
the acquired thrombophilia of the antiphospholipid syn-
drome, seen with lupus anticoagulant and/or anticardiol-
ipin antibody seropositivity, is strongly associated with
recurrent fetal loss[1]. In the literature, various hereditary
thrombophilias such as activated protein C resistance, the
factor V leiden mutation (both homozygosity and hetero-
zygosity), the prothrombin G20210A mutation, protein S
deficiency, the methylenetetrahydrofolate reductase
(MTHFR) C677T mutation, hyperhomocysteinemia, or
combinations of the above disorders have also been
linked to pregnancy loss at varying stages of gestation
[2,3]. Yet because many of the published case series and
meta-analyses describe conflicting results, the relation-
ship between a MTHFR mutation and recurrent miscar-
riages remains confusing. We present eight cases from our
institution that may well represent the impact of homozy-
gosity of the MTHFR C677T mutation on early pregnancy
loss.
Case series
Eight women presented within a span of three months to
our institution with histories of one or more miscarriages
after the 10th  week of gestation. These women were
referred to our program after their obstetricians had
excluded common causes of fetal loss. None of these
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women had TORCH infections or gestational diabetes,
and karyotype analyses on the products of conception
(when possible) were normal. We were asked, in each
case, to evaluate for thrombophilia as a cause of recurrent
miscarriage and to determine if intervention (anticoagula-
tion) would help to prevent future miscarriages. Each of
these women denied a personal or family history of
thrombosis.
For each patient, blood tests for both genetic and acquired
causes of thrombophilia were performed (see Table 1).
Pregnancy loss after the 10th week of gestation has been
more closely associated with thrombophilia, as opposed
to earlier losses in weeks 3 to 9[4]. The mean age of these
women was 36 years, and the number of previous miscar-
riages ranged from 1 to 6. The clinical features of each case
and the results of the thrombophilia work-ups are
reported in Table 2. Each patient was found to be
homozygous for the MTHFR C677T mutation. One
patient was also heterozygous for the MTHFR A1298C
mutation, three were heterozygous for the PAI-1 gene pol-
ymorphism 4G/5G, and one was homozygous for the
PAI-1 gene polymorphism 4G/4G. Not surprisingly,
homocysteine levels were in normal range for each
patient, as they were each taking prenatal vitamins.
We reviewed the literature in order to find evidence to
support or refute the association between MTHFR muta-
tions and adverse pregnancy outcomes, and to guide us in
managing these patients. Patients 1, 2, 3, 7 and 8 were
seen hoping to become pregnant again, while patients 4,
5 and 6 were already pregnant and not as yet anticoagu-
lated.
Results
We recommended treatment doses of low-molecular
weight (LMW) heparin as a therapeutic intervention in
hopes of achieving a full-term pregnancy and reducing the
risk of recurrent abortion for future pregnancies. Patients
4 and 6 who were pregnant received LMW heparin imme-
diately. Unfortunately, patient 5 miscarried prior to start-
ing LMW heparin, but was able to conceive again and
received LMW heparin shortly after this next conception.
We recommended LMW heparin upon conception for
patients 1, 2, 3, 7 and 8 who were not yet pregnant. As
seen in Table 2, two women had successful full-term deliv-
eries on LMW heparin, while a third woman is currently
pregnant (in her third trimester) and has been taking
LMW heparin since conception. Five patients are trying to
conceive.
Discussion
Methyltetrahydrofolate reductase is an enzyme which cat-
alyzes the reduction of 5, 10-methyltetrahydrofolate and
allows the re-methylation of homocysteine to methionine
[5]. A variant form of 5-MTHFR, termed "thermolabile"
because of poor heat stability in vitro, was first described
in 1988, and was found to be associated with the develop-
ment of coronary artery disease. Homozygosity for the
gene encoding this thermolabile mutant provides only
50% of normal MTHFR enzyme activity, and can lead to
hyperhomocysteinemia [6]. Over the past two decades,
multiple reports have cited the MTHFR mutation as a risk
factor for both thrombosis and pregnancy loss, while oth-
ers have refuted the association. Exactly how MTHFR
mutations can cause pregnancy complications is
unknown; a logical hypothesis is that endothelial damage
from hyperhomocysteinemia leads to venous throm-
boemboli and placental insufficiency. In a retrospective
study of 24 Indian women with recurrent pregnancy loss,
the highest values of homocysteine were found in those
who carried the MTHFR gene[7]. However, other reports
refute this hypothesis. Another study compared homo-
cysteine levels in 57 pregnant women with and without
the MTHFR C677T mutation and found that homo-
cysteine concentrations were not different by MTHFR gen-
otype[8], suggesting that fetal loss associated with the
MTHFR mutation can be seen in the absence of high
homocysteine levels. Indeed, this is what we saw in our
four patients, who are homozygous for the C677T muta-
tion and have had several miscarriages, yet their homo-
cysteine levels were always normal. Therefore, a different
mechanism for fetal loss, less dependant on hyperhomo-
cysteinemia, may exist.
Interestingly, patient 1 described an episode of transient
spontaneous bilateral hearing loss seven years prior. Tran-
sient hearing loss can be caused by vascular insufficiency
and is associated with MTHFR mutations [9]. Of note,
Table 1: Hypercoaguability Profile
Fibrinogen
Factor VIII
Factor IX
Factor XI
Anti-Phosphatidyl Serine IgG
β2 Glycoprotein
Anti-Cardiolipin IgM and IgG
Lupus anticoagulant
Plasminogen
Euglobulin clot lysis
Homocysteine
Factor V Leiden
Prothrombin G20210A allele
Protein C
Protein S
Antithrombin III
5,10 MTHFR gene
PAI-1 polymorphism gene
Activated Protein C resistanceThrombosis Journal 2007, 5:17 http://www.thrombosisjournal.com/content/5/1/17
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patient #2 is additionally heterozygous for another
MTHFR mutation, A1298C, the second most common
mutant polymorphism of the MTHFR mutant gene. It is
estimated that 15–20% of the general population are het-
erozygous for one of the two variants, with prevalence
even higher in certain ethnicities[10]. However, the
A1298C polymorphism has never been reported as a
cause of recurrent fetal loss, and has no role in causing
thrombophilia [11].
MTHFR mutations have been linked to various adverse
pregnancy outcomes: specifically, early fetal loss (most
commonly defined as spontaneous abortion in the first or
second trimester), late fetal loss (death in the third trimes-
ter), preecclampsia, intrauterine growth retardation, pla-
cental abruption and neural tube defects. We found it
difficult to find clear evidence for or against the associa-
tion between MTHFR mutations and the pregnancy out-
comes listed above. Much of the data supporting a
causative association is in the form of isolated case reports
and small case series, which have been excluded from the
larger meta-analyses discussed below[2,12,13]. Also, the
definition of recurrent fetal loss varies widely among stud-
ies with respect to number of previous losses (1 to 3), the
timing of losses (consecutive vs. non), and the age of ges-
tational loss (less than 12 weeks through less than 24
weeks), making it difficult to interpret the data and com-
pare the studies. There are a number of retrospective and
case-control studies demonstrating a significantly higher
frequency of MTHFR mutations in patients with recurrent
fetal loss than in the control groups [14-16]. An often-
cited study supporting the role of MTHFR mutations in
recurrent unexplained abortions found a 2–3 fold
increased risk of early fetal loss among 185 Caucasian
females homozygous for the C677T mutation versus 113
normal controls[17]. These studies, combined with
numerous case reports, strongly suggest a significant asso-
ciation between recurrent miscarriage and the mutant
MTHFR allele.
Recent meta-analyses have pooled several of these and
other studies, and concluded that in most cases the rela-
tionship between MTHFR mutations and adverse preg-
nancy outcomes is not truly significant. One meta-
analysis of ten studies specifically addressing MTHFR
mutations and hyperhomocysteinemia found an odds
ratio of 1.4 favoring higher risk of recurrent pregnancy
loss, but the confidence interval was 1.0–2.0[12]. A sec-
ond meta-analysis pooled eight studies of recurrent and
six of non-recurrent fetal loss, and found no association
between homozygous MTHFR mutations and either clini-
cal outcome [13]. And finally, the third and largest meta-
analysis of thrombophilia in pregnancy found no associ-
ation between MTHFR mutant homozygosity and venous
thromboembolism or recurrent first trimester loss. There
was a trend toward higher risk in the pooled analyses for
non-recurrent early loss and late loss, but both confidence
intervals crossed the one. This meta-analysis did find that
patients with MTHFR mutant homozygosity are at
increased risk of pre-ecclampsia, with a odds ratio of 1.37
reaching statistical significance [2].
Given the above data, we as clinicians are left with a
dilemma of whether or not to recommend anticoagula-
tion for patients such as these. Again, we feel that defini-
tive evidence for or against the association of MTHFR
mutations and adverse pregnancy outcomes is lacking.
Admittedly, there are limitations of meta-analyses as well
as the smaller positive studies. Many published case
reports describe successful pregnancy outcomes with the
prophylactic use of anticoagulation (most commonly
low-molecular weight heparin) in women with MTHFR
mutations and multiple recurrent miscarriages. However,
no randomized studies exist to address the use of antico-
agulation in pregnant women with MTHFR mutations.
We found one study in which 351 women with recurrent
miscarriages (12% with the MTHFR mutation) were
treated with prophylactic asprin + unfractionated or LMW
heparin to term; the success rate of normal term delivery
in this study was 94% [18].
Treatment of 3 patients with LMW heparin during preg-
nancy led to successful deliveries in two women, while
another woman is pregnant in her third trimester with no
complications thus far and is scheduled for induction. We
plan to treat patients 1, 2, 5, 7 and 8 with LMW heparin
once they become pregnant. An eighth patient with no
history of fetal loss presented in consultation after a
Table 2: Patient Data
Patient Age Miscarriages Normal births Defect Outcome on LMW heparin
1 27 2 in first trimester 1 in second trimester 1 MTHFR C677T homozygous A1298C heterozygous N/A
2 41 2 in first trimester 0 MTHFR C677T homozygous N/A
3 39 2 in first trimester 1 MTHFR C677T homozygous PAI-1 heterozygous 4G/5G Pregnancy with successful delivery
4 44 2 in first trimester 0 MTHFR C677T homozygous Pregnancy with successful delivery
5 27 1 in first trimester 3 MTHFR C677T homozygous PAI-1 heterozygous 4G/5G N/A
6 34 6 in first trimester 3 MTHFR C677T homozygous PAI-1 heterozygous 4G/5G Pregnant, in third trimester
7 32 2 in first trimester 2 MTHFR C677T homozygous N/A
8 40 3 in first trimester 0 MTHFR C677T homozygous PAI-1 homozygous 4G/4G N/APublish with BioMed Central    and   every 
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hypercoaguable work-up was performed prior to the
planned use of hormonal agents to treat infertility (not
detailed). She too is homozygous for the MTHFR muta-
tion, in addition to being a carrier of the PAI-1 polymor-
phism. We recommended anticoagulation for this patient
as well.
Conclusion
Although our report is also a case series, we feel it adds to
the literature that the relationship between MTHFR
C677T homozygosity and spontaneous abortions may be
real, and we are encouraged that treatment with LMW
heparin appears to have led to two successful deliveries
and one uncomplicated near-complete pregnancy thus
far. Only this kind of surveillance and reporting will estab-
lish whether this relationship will hold up over time.
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